Breast Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026
Breast Cancer Emerging Therapy and TPP Insights Thelansis’s “Breast Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Breast Cancer Overview Breast cancer is the most common malignancy in women worldwide, classified into hormone receptor‑positive (HR+), HER2‑positive, and triple‑negative (TNBC) subtypes. Early‑stage disease is managed with surgery, radiation, and subtype‑specific adjuvant systemic therapy. In advanced disease, precision medicine has transformed care: endocrine therapy plus CDK4/6 inhibitors is standard for HR+ disease; HER2‑targeted therapies and ADCs (trastuzumab deruxtecan, T‑DM1) are central for HER2+ and HER2‑low tumors; and sacituzumab govitecan and immunotherapy (pembrolizumab for PD‑L1+ TNBC) provid...